enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Teva Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Teva_Pharmaceuticals

   Teva Pharmaceutical Industries took its present form through the efforts of Günther Friedländer and his aunt Else Kober on May 1, 1935. The original registration was under the name Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem, then part of Mandatory Palestine. Friedländer was a German pharmacist, botanist and ...

3. Ratiopharm - Wikipedia

   en.wikipedia.org/wiki/Ratiopharm

   On 18 March 2010 Teva announced that it planned to acquire Ratiopharm for US$5 billion. [1] [2] On 10 August 2010 Teva announced that it had completed its acquisition of Ratiopharm. [3] Since June 2017, the company has been managed by Christoph Stoller, General Manager of Teva Germany and Austria (European headquarters). [4]

4. Teva launches generic version of Novo Nordisk's ... - AOL

   www.aol.com/news/teva-launches-generic-version...

   (Reuters) -Teva Pharmaceuticals said on Monday it had launched a generic version of Novo Nordisk's Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the ...

5. Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes

   www.aol.com/finance/teva-pays-450m-resolve...

   Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) has agreed to a $450 million settlement with the U.S. government to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the ...

6. Pliva - Wikipedia

   en.wikipedia.org/wiki/Pliva

   Pliva headquarters in Zagreb Azithromycin, also known as Sumamed, is one of the world's best-selling antibiotics.. Pliva d.o.o. is a pharmaceutical company based in Zagreb, Croatia that primarily manufactures and sells generic drugs.

7. Teva Pharm to stay as unified drugmaker, sees big interest in ...

   www.aol.com/news/teva-pharm-stay-unified...

   Teva has several biosimilars - copies of high-priced drugs - and net debt is down to $16.6 billion. High debt from a failed acquisition in 2017 has held Teva back from further M&A deals, Francis said.